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Abstract
The neuromuscular junction has retained through evolution the
capacity to regenerate after damage, but little is known on the
inter-cellular signals involved in its functional recovery from
trauma, autoimmune attacks, or neurotoxins. We report here that
CXCL12a, also abbreviated as stromal-derived factor-1 (SDF-1), is
produced specifically by perisynaptic Schwann cells following
motor axon terminal degeneration induced by a-latrotoxin.
CXCL12a acts via binding to the neuronal CXCR4 receptor. A
CXCL12a-neutralizing antibody or a specific CXCR4 inhibitor
strongly delays recovery from motor neuron degeneration in vivo.
Recombinant CXCL12a in vivo accelerates neurotransmission
rescue upon damage and very effectively stimulates the axon
growth of spinal cord motor neurons in vitro. These findings indi-
cate that the CXCL12a-CXCR4 axis plays an important role in the
regeneration of the neuromuscular junction after motor axon
injury. The present results have important implications in the
effort to find therapeutics and protocols to improve recovery of
function after different forms of motor axon terminal damage.
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Introduction
The neuromuscular junction (NMJ) is a specialized tripartite
synapse formed by the motor axon terminal (MAT) and the muscle
fiber (MF), which are separated by a basal lamina (BL), and covered
by perisynaptic Schwann cells (PSCs). This is the best-studied
synapse, and most of what is presently known about development,
structure, and function of a synapse derives from studies on the
NMJ. The NMJ is not protected by anatomical barriers, and it is
subjected to traumas and to the attack of many pathogens, including
neurotoxins and autoimmune antibodies. For these reasons and for
its essential role in life and survival, the NMJ, unlike the central
nervous system synapses, has retained throughout vertebrate evolu-
tion the capacity to regenerate (Brosius Lutz & Barres, 2014).
Damaged MATs regenerate readily forming new NMJs that look and
perform as the original ones (Son et al, 1996; Sanes & Lichtman,
1999; Darabid et al, 2014). Hence, the NMJ is a privileged system to
study the inter- and intracellular signaling occurring during MAT
degeneration and, more importantly, of those governing the ensuing
regeneration.
We have recently established a murine model of NMJ degenera-
tion and regeneration based on the specific and acute actions of
a-latrotoxin (a-LTx) or of snake presynaptic PLA2 neurotoxins
(Dixon & Harris, 1999; Rigoni et al, 2004, 2005; Ushkaryov et al,
2008), with the aim of identifying the molecules involved in intra-
and inter-cellular signaling governing NMJ regeneration (Duregotti
et al, 2015; Rigoni & Montecucco, 2017). These neurotoxins bind
specifically to the presynaptic membrane and induce a large Ca2+
entry into nerve terminals, with exocytosis of synaptic vesicles,
rounding and degeneration of mitochondria, and Ca2+-induced acti-
vation of hydrolases such as calpains (Rigoni et al, 2007, 2008;
Tedesco et al, 2009; Duregotti et al, 2013). This causes the
complete MAT degeneration with formation of debris that are
phagocytosed by PSCs, without recruitment of inflammatory cells.
PSCs become activated during MAT degeneration by signals which
include mitochondrial and cytosolic alarmins (Duregotti et al, 2015;
Negro et al, 2016). PSCs play an essential role in regeneration, not
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limited to the clearing of necrotic debris (Son et al, 1996; Sanes &
Lichtman, 1999; Jessen et al, 2015). Stimulated PSCs, together with
MF, are believed to produce and release a series of factors that act
on the motor axon stump inducing its growth until contacts with
the BL are re-established, with resumption of regulated neurotrans-
mitter release (Son et al, 1996; Sanes & Lichtman, 1999; Darabid
et al, 2014).
In mice, the entire degeneration and regeneration process
induced by a-LTx is completed within about 5 days with no
apparent inflammatory response, thus making the task of identify-
ing inter-cellular signals simpler. We carried out a transcriptome
analysis of the NMJ at different time points after injection of
a-LTx, to identify novel intra- and inter-cellular signaling mole-
cules. Among the many messenger RNAs (mRNAs) differentially
expressed during degeneration and regeneration, we investigated
the role of the chemokine CXCL12a (also abbreviated as stromal-
derived factor 1, SDF-1). Here, we provide compelling evidence
that CXCL12a is produced by activated PSCs and plays an impor-
tant role in NMJ regeneration by inducing the growth of the
motor axon.
Results
CXCL12a mRNA increases during NMJ degeneration
To determine the transcriptome program of murine NMJs during
acute degeneration of MAT followed by complete regeneration, we
used an animal model that we recently developed (Duregotti et al,
2015). The time course of a-LTx-induced reversible degeneration
was defined by staining over time the presynaptic markers SNAP25
(synaptosomal-associated protein 25) and VAMP1/synaptobrevin. We
employed transgenic mice expressing a cytosolic GFP in Schwann
cells (SCs) under the plp promoter (Mallon et al, 2002) to visualize
PSCs. In Levator auris longus (LAL) muscles (Angaut-Petit et al,
1987) injected with a-LTx, there is a progressive fragmentation of
presynaptic nerve terminals that peaks at 4 h; with time, a gradual
reappearance of SNAP25 (Fig 1A) and VAMP1 (Fig 1B) takes place,
with the motor axon end plate returning similar to controls by 96 h.
Therefore, we performed a transcriptome analysis of NMJs from LAL,
a muscle very suitable for NMJs collection by laser microdissection,
from samples taken at 4, 24, 96 h after a-LTx injection. Total RNA
was extracted, quality-controlled, retro-transcribed, amplified, and
sequenced (Fig EV1), and results were compared with those of
controls.
Among the mRNAs differentially expressed during MAT degener-
ation and regeneration, we focused on the one encoding for
CXCL12a, which is poorly expressed in controls, upregulated at 4 h
(MAT degenerated and active phagocytosis of debris by PSCs), and
returns to low expression later on (Fig 1C). Such pattern of
CXCL12a mRNA change with time was confirmed also in soleus
muscle by droplet digital PCR (Figs 1D and EV2).
CXCL12a was previously reported to play an active role in
neuronal development (Lieberam et al, 2005; Arno` et al, 2014;
Shellard & Mayor, 2016). Given that development and regeneration
may share molecules and signaling pathways, we tested the possi-
bility that CXCL12a plays a role in the regrowth of the motor axon
stump to reform a functional NMJ.
CXCL12a is expressed by PSCs during NMJ degeneration
The sampling protocol developed here provides RNA from MAT,
PSCs, and MF at the same time; therefore, RNA transcripts cannot
be directly attributed to one cell type. To identify the cellular origin
of CXCL12a, we performed at the NMJ both fluorescence in situ
hybridization (FISH) and immunohistochemistry. CXCL12a mRNA
signal is barely detectable in control NMJs, but becomes evident
4 h post-injection within PSCs (Fig 1E). Using a specific antibody,
we found that CXCL12a is contained inside PSCs granules
(56  5% of CXCL12a-positive NMJs; Fig 1F, arrows and orthogo-
nal projection). In agreement with the transcriptomic profile, the
intensity of CXCL12a staining decreases with time, becoming prac-
tically absent at 96 h, when regeneration is well under way. These
data indicate that the production of this chemokine by PSCs is an
early event.
Neutralization of CXCL12a delays NMJ regeneration in vivo
CXCL12 knockout mice are not viable (Nagasawa et al, 1996), and
in conditional CXCL12a knockout mice protein disappearance is
incomplete (Arno` et al, 2014). To assess whether CXCL12a plays a
role in the regeneration of damaged NMJs, we followed the classical
approach used for nerve growth factor (Angeletti et al, 1971). We
injected intraperitoneally a CXCL12a-neutralizing IgG monoclonal
antibody before a-LTx injection in the mice hind limb. By this
approach, the biochemical knockout of the chemokine begins
rapidly after antibody injection and lasts for a long time, as the half-
life of murine IgG antibodies exceeds 11 days (Sigounas et al,
1994). Recovery of muscle contraction was measured by recording
the evoked junctional potentials: NMJ regain of function is signifi-
cantly delayed at 72 and 96 h in the presence of the anti-chemokine
antibody (Fig 2A), in line with its slower anatomical recovery, as
assessed by immunostaining the presynaptic marker VAMP1
(Fig EV3). Injection of the sole anti-chemokine antibodies has no
effect on neurotransmission. As expected, the impairment of regen-
eration is not complete, given that the process is driven and
governed by a set of factors (Sanes & Lichtman, 1999; Darabid et al,
2014). In this light, the effect of CXCL12a on nerve recovery of func-
tion is even more remarkable.
CXCL12a promotes axonal growth in cultured spinal cord
motor neurons
In cultured cerebellar and hippocampal neurons, CXCL12a was
shown to promote axonal elongation (Arakawa et al, 2003; Pujol
et al, 2005). Accordingly, we tested the effect of recombinant
CXCL12a (rCXCL12a) on primary cultures of spinal cord motor
neurons (SCMNs) grown in culture dishes (Arce et al, 1999).
Figure 2B shows that rCXCL12a (500 ng/ml) strongly stimulates
axon elongation, and panel C provides a quantitative estimation of
this effect. This concentration was used before (Opatz et al, 2009;
Heskamp et al, 2013), and it appears appropriate if one considers
that the chemokine is released from PSCs into the very small
volume between nerve terminals and PSCs. The growth-promoting
effect of CXCL12a can be better appreciated in microfluidic
devices, which consist of a somatic chamber, where neurons are
plated, connected to a distal chamber, containing the chemokine,
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via parallel micrometer-size grooves, within which the axons grow
(Park et al, 2006; Zahavi et al, 2015; Fig 2D–F). In these microflu-
idic plates, the stimulus is applied directionally as a gradient from
the distal chamber versus the axon tip. An additional advantage
of these devices is that one can measure number and length of
single axons growing within the groove. rCXCL12a failed to
promote axonal elongation when applied to the somatic chamber,
suggesting that it acts by interacting with axonal receptors
(Fig EV4).
Remarkably, local administrations of rCXCL12a after neurotoxin
injection in the mice soleus muscle accelerated the functional recov-
ery of degenerated nerve terminals, as assessed by electrophysiolog-
ical recordings (Fig 2G).
The CXCL12a-CXCR4 axis directs motor axon growth in vivo
and in vitro
In the immune and nervous systems, CXCL12a signals mainly via
the CXCR4 receptor (Chalasani et al, 2003; Lieberam et al, 2005;
Pujol et al, 2005; Guyon, 2012; Nagasawa, 2014). This receptor is
well expressed in cultured SCMNs: it concentrates at the growing tips
of axons (Fig 3A, arrow), similar to what found in isolated brain
neurons in vitro (Arakawa et al, 2003; Pujol et al, 2005), and co-
localizes with the typical growth cone-associated marker GAP43
(Fig 3B).
In the adult NMJs, CXCR4 signal is almost undetectable, but
becomes evident in the motor axon stump upon a-LTx-induced
degeneration (Fig 3C), reminiscent of the transient expression of
CXCR4 in developing spinal cord neurons (Lieberam et al, 2005).
No CXCR4 was detected by antibody staining in PSCs, nor it was
revealed by our NMJ transcriptome analysis, which does not include
mRNAs from neuronal cell bodies.
AMD3100 is a specific CXCR4 antagonist (De Clercq et al,
1992; Donzella et al, 1998). When AMD3100 was applied to the
somatic chamber of microfluidic devices, the promotion of axon
growth exerted by rCXCL12a was reduced (Fig 3D and E). The
same result was obtained with SCMNs grown in culture dishes
(Fig EV5).
AMD3100, administered intraperitoneally in mice, delays NMJ
recovery from paralysis caused by a local injection of a-LTx in the
hind limb, monitored by electrophysiology (Fig 3F). This result
provides a pharmacological evidence of the involvement of a func-
tional CXCL12a-CXCR4 axis in NMJ regeneration in vivo.
The CXCL12a-CXCR4 axis is modulated by the atypical chemo-
kine receptor 3 (ACKR3; Cruz-Orengo et al, 2011; Bachelerie et al,
2013), which acts as a scavenger for the chemokine (Naumann
et al, 2010; Abe et al, 2014). However, we did not detect ACKR3 on
nerve terminals of LAL muscle in transgenic mice expressing the
GFP-ACKR3 construct (Cruz-Orengo et al, 2011; not shown).
Altogether, these findings indicate that the CXCL12a-CXCR4 axis
operates in MAT recovery of function after an acute degeneration,
supporting the view that NMJ regeneration recapitulates at least
some of the events underpinning its development (Sanes & Lichtman,
1999; Darabid et al, 2014).
Discussion
The major findings of the present paper are as follows: (i) CXCL12a
is produced at the adult NMJ by PSCs activated by signals from
injured motor axon terminals; (ii) this chemokine plays a relevant
role in the process of NMJ regeneration in vivo by interacting with
the receptor CXCR4 expressed on the motor neuron stump. These
results have a double value: a translational one, as rCXCL12a could
be included in a mixture of factors to be used to regenerate damaged
NMJs, and a basic science indication that MAT regeneration recapit-
ulates, at least in part, motor neuron development.
These results were obtained with an acute model of MAT degen-
eration and regeneration, which is highly reproducible and has a
well-defined time course. Moreover, there appears to be little, if
any, inflammation, differently from the “classical” cut and/or crush
models (Rigoni & Montecucco, 2017). This model is therefore not
blurred by inflammatory mediators in the search of signals
exchanged among the partners of the NMJ, thus allowing one to
identify immune signals possibly involved in the nervous system, as
it is the case of the present work.
We have defined the time course of a-LTx-induced MAT degener-
ation and regeneration by immunostaining the NMJs of LAL, a very
thin mice muscle composed of few fiber layers (Angaut-Petit et al,
1987), very suitable for imaging and collection of NMJs by laser
microdissection, and by immunostaining and electrophysiology of
the soleus muscle. Four time points were selected to determine the
mRNA profile of mice NMJs during degeneration and subsequent
recovery by transcriptomics.
We found that CXCL12a mRNA is upregulated during MAT
degeneration and then returns to basal levels when regeneration is
◀ Figure 1. CXCL12a is expressed by perisynaptic Schwann cells during nerve terminal degeneration.A, B The time course of motor axon terminal degeneration and regeneration induced by a-LTx at LAL NMJs was determined in mice with GFP-expressing SCs (green),
using the presynaptic markers SNAP25 (red) (A) and VAMP1 (red) (B); at 4 h, SNAP25 and VAMP1 are phagocytosed inside PSCs. Muscles were fixed 0, 4, 24, and
96 h post-injection. Scale bars: 10 lm.
C CXCL12a mRNA levels (expressed as FPKM, fragments per kilobase of exon per million fragments mapped) during MAT degeneration and regeneration induced by
a-LTx at LAL NMJs. Data are presented as mean  SD. *P = 0.017 (ctr vs. 4 h), three independent experiments. Statistical analysis was performed by Cuffdiff
software.
D CXCL12a mRNA levels measured by droplet digital PCR performed on cDNA from soleus muscles locally injected with a-LTx (0, 4, 16, and 72 h). The time points
analyzed were chosen on the basis of the time course of nerve terminal degeneration and regeneration by a-LTx poisoning in soleus muscle, which is slightly
different from that of LAL. Nonetheless, in both muscles degeneration peaks at 4 h (Fig EV2). Data are expressed as fractionary abundance with respect to the
housekeeping GAPDH, five independent experiments. Data are presented as mean  SD. ****P < 0.0001 (4 h vs. ctr, 16 and 72 h) by ANOVA with post hoc Tukey test.
E In situ CXCL12a mRNA hybridization (white) at soleus NMJ before and after 4-h intoxication with a-LTx. PSCs are in green. Representative images are shown.
Scale bars: 10 lm.
F Immunostaining for CXCL12a (white, arrows) at LAL NMJs in controls and after 4, 24, and 96 h of intoxication. PSCs are in green. Scale bars: 10 lm. Right:
Orthogonal projection of a-LTx-poisoned NMJ (4 h) shows that CXCL12a spots are inside PSCs (arrows). Scale bar: 10 lm.
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Figure 2. The chemokine CXCL12a plays an important role in nerve terminal regeneration in vivo.
A Evoked junctional potentials (EJPs) recorded in soleus muscles 48, 72 and 96 h after a-LTx injection in the mice hind limb, with/without a previous intraperitoneal
administration of a CXCL12a-neutralizing antibody. Controlateral muscles (injected with saline) were used as controls. Muscles injected with the sole neutralizing
antibody show EJPs similar to controls. Each bar represents mean  SEM from six animals, 15 EJPs measured per animal. *P = 0.03 (72 h) and *P = 0.017 (96 h) by
Student’s t-test, unpaired, two-sided.
B, C CXCL12a promotes axon growth of primary SCMNs. rCXCL12a (500 ng/ml) was added to SCMNs plated in culture dishes. After 24 h, neurons were fixed and stained
for b3-tubulin (green). Scale bar: 10 lm. Quantification is shown in (C). Each bar represents the mean  SD from five different experiments, 70 neurons measured
per experiment. ***P = 0.0003 by Student’s t-test, unpaired, two-sided.
D Microfluidic devices employed in the study. Somatic chambers are separated from the distal ones by a series of grooves along which SCMNs axons grow (cells
plated in the somatic compartment).
E, F rCXCL12a (500 ng/ml) added to the distal chamber promotes axonal elongation of SCMNs plated in the somatic chamber of microfluidic devices. The figure shows
the distal chamber after 5 days of culture. Scale bars: 50 lm. Panel (F) shows the quantification of axon growth from nine experiments. Data are presented as
mean  SD. **P = 0.0019 by Student’s t-test, unpaired, two-sided.
G Evoked junctional potentials (EJPs) recorded in soleus muscles 72 h after a-LTx injection in the mice hind limb, with/without local administrations of rCXCL12a.
Controlateral muscles were used as controls. Each bar represents mean  SEM from nine animals, 15 EJPs measured per animal. **P = 0.0043 by Student’s t-test,
unpaired, two-sided.
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Figure 3. The CXCL12a-CXCR4 axis participates in the regeneration of the NMJ in vivo.
A, B CXCR4 (red) is expressed by primary SCMNs (b3-tubulin positive, green) and accumulates in growing tips (arrows). Panel (B) shows CXCR4 co-localization with the
growth-cone marker GAP43 (green). Scale bars: 10 lm.
C CXCR4 (white) is almost undetectable in control NMJs from LAL muscles, and it becomes evident in nerve terminals (SNAP25-NF positive, red) poisoned by a-LTx
(16-h intoxication). GFP-expressing SCs are in green. Scale bars: 10 lm.
D, E AMD3100 reduces the axon elongation stimulating ability of rCXCL12a on SCMNs in microfluidic chambers. Axon growth was measured after 5 days of treatment.
Scale bars: 10 lm. Quantification is shown in (E). Each bar represents mean  SD from six different experiments, 70 neurons measured per experiment.
****P < 0.0001 by ANOVA followed by post hoc Tukey test.
F Intraperitoneal administration of the CXCR4 antagonist AMD3100 delays the functional recovery of mice NMJs exposed to a-LTx. Each bar represents mean  SEM
from six animals, 15 EJPs measured per animal. **P = 0.0057 by Student’s t-test, unpaired, two-sided.
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nearly completed. The mRNA and the encoded chemokine are
specifically expressed by PSCs, arguably by the stimulation of
factors released by degenerating MAT, providing a compelling
molecular evidence of the active and direct involvement of PSCs in
the recovery of function of the damaged NMJ. This finding supports
the idea that an intense inter-cellular signaling takes place among the
three partners of the NMJ not only during development (Sanes &
Lichtman, 1999; Darabid et al, 2014), but also during regeneration in
adulthood.
In the present work, the role of CXCL12a has been first tested
in vivo, and a clear delay in regeneration was found when the
chemokine was neutralized by a specific antibody. This result is
remarkable if one considers that nerve regeneration is driven and
assisted by an array of factors (Sanes & Lichtman, 1999; Darabid
et al, 2014), and we neutralized only one of them by a single dose
of a monoclonal antibody delivered systemically. This in vivo action
of CXCL12a is most likely exerted via an elongation promotion
effect on the motor axon, as suggested by experiments performed
in vitro in neurons grown in microfluidic devices, where axon
growth can be visualized and quantified. In addition, local adminis-
tration of the recombinant chemokine accelerates NMJ functional
recovery, in support of its promising therapeutic value.
CXCL12a signals via the receptor CXCR4, as suggested by the
inhibitory activity in vivo of growth of the motor axon stump after
MAT degeneration exerted by the CXCR4-specific antagonist
AMD3100. This result is fully consistent with the effect of the anti-
CXCL12a antibody: both agents delayed significantly the recovery of
the paralyzed NMJs. Noteworthy, CXCR4 was detected by immunos-
taining at the tip of growing axons, and AMD3100 reduced the axon
growth-stimulating activity of the chemokine. CXCR4 expression
becomes detectable in vivo upon a-LTx-induced degeneration,
supporting the involvement of this axis in axon regrowth. The
absence of CXCR4 in vivo in PSCs excludes the possibility that
CXCL12a has an autocrine effect, in agreement with the previous
finding that in vitro the chemokine induces the death of primary SCs
(Ku¨ry et al, 2003). In addition, the in vitro promotion of axonal
growth by CXCL12a and the expression of CXCR4 in SCMNs indicate
that primary neuronal cultures are an in vitro model of regeneration
more than of development. As such, they appear an appropriate
counterpart of the in vivo experiments based on antibodies and
specific inhibitors reported here.
CXCL12 was discovered following a screening for proteins
endowed with a secretion signal sequence (Tashiro et al, 1993), and
soon after as a stroma-derived factor capable of stimulating the
growth of the pre-B-cell population within the bone marrow, and
termed therefore stromal cell-derived factor 1 (SDF-1; Nagasawa
et al, 1994). Three variants of CXCL12 have been identified in mice:
a, b, and c. The latter isoform is resident in the nucleus, while the
beta isoform is expressed by endothelial cells and appears to play a
major role in leukocytes recruitment. CXCL12a is involved in the
development of various regions of the central nervous system (Bagri
et al, 2002; Chalasani et al, 2003; Lieberam et al, 2005), and the
CXCL12-CXCR4 axis regulates a variety of responses in the immune
and nervous systems (Lu et al, 2002; Stumm et al, 2003; Lieberam
et al, 2005; Zhu et al, 2009; Guyon, 2012).
In the present work, CXCL12a was found to be produced by PSCs
at the NMJs, using a combined mRNA and protein analysis. This is
the first evidence for an important and defined role of CXCL12a in
the regeneration of the NMJ after MAT damage, and in the axon
growth of SCMNs in culture. These results might have translational
applications in the formulation of a mixture of growth factors to
improve the functional recovery of the NMJ after various types of
damage, including genetic neurodegenerative syndromes, and in
spinal cord diseases characterized by motor neuron loss.
Materials and Methods
Antibodies and toxins
The following primary antibodies were employed: anti-SNAP25
(mouse monoclonal, SMI81, mouse monoclonal, Covance, catalogue
836301, 1:200), anti-VAMP1 (rabbit polyclonal, 1:200, Rossetto
et al, 1996), anti-CXCL12a (mouse monoclonal, R&D, catalogue
mab350, 1:50), anti-b3-tubulin (rabbit polyclonal, Synaptic System,
catalogue SYSY 302302, 1:200), anti-CXCR4 (rabbit polyclonal,
Abcam, catalogue ab7199, 1:50–500), anti-GAP43 (rabbit mono-
clonal, Abcam, catalogue ab75810, 1:200), anti-neurofilaments (NF)
200 (mouse monoclonal, Sigma, catalogue N0142, 1:200), a-bungar-
otoxin (a-BTx, Life Technologies, catalogue B35451, 1:200).
Secondary antibodies Alexa-conjugated (1:200) were from Life
Technologies.
Purified a-LTx was purchased by Alomone (catalogue LSP-130).
The purity of the toxin was checked by SDS–PAGE and its neurotox-
icity by ex vivo mouse nerve-hemidiaphragm preparations as previ-
ously described (Rigoni et al, 2005). Unless otherwise stated, all
reagents were purchased from Sigma.
Ethical statement
C57BL/6 mice expressing cytosolic GFP under the plp promoter
(Mallon et al, 2002) were kindly provided by Dr. W.B. Macklin
(Aurora, Colorado) with the help of Dr. T. Misgeld (Munchen,
Germany). All experimental procedures involving animals and their
care were carried out in accordance with National laws and policies
(D.L. n. 26, March 14, 2014) and with the guidelines established by
the European Community Council Directive (2010/63/UE) and were
approved by the local authority veterinary services.
Sample preparation for laser microdissection
Upon isoflurane anesthetization, 2-month-old transgenic C57BL/6
female mice of around 20–25 g were locally injected with a-LTx
close to the LAL muscles. Animals were randomized in the experi-
mental groups based on their body weight. The toxin (5 lg/kg) was
diluted in 15 ll of physiological saline (0.9% w/v NaCl in distilled
water). Control animals were injected with saline. At different time
points (0, 4, 24, and 96 h), treated mice were sacrificed by anes-
thetic overdose followed by cervical dislocation and LAL muscles
were immediately fixed with a local injection of 4% PFA for 10 min.
Muscles were collected, incubated with fluorescent a-BTx in sterile
PBS for 30 min at 37°C, and then frozen in liquid nitrogen. Cryosec-
tions (7 lm thick) were transferred to UV-treated microscope glass
slides. Microdissection was performed under direct microscopic
visualization with PALM RoboMover automatic laser microdissector
(Carl Zeiss, Oberkochen, Germany).
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RNA isolation
Total RNA was isolated from the microdissected samples by incuba-
tion with 50 ll of lysis buffer PKD (Qiagen, Venlo, Netherlands) and
10 ll of proteinase K solution (Promega, Madison, WI, USA) at 55°C
overnight with the sample upside down. The day after samples were
centrifuged for 10 min at 6,700 g and RNA extracted using the
Maxwell 16 LEV RNA FFPE Purification Kit (Promega) following
manufacturer’s instructions.
To prepare cDNA from RNA samples, the SMARTer Universal
Low Input RNA kit (Clontech Laboratories) was employed following
manufacturer’s instructions. Libraries were prepared using the Ion
TargetSeq Exome Enrichment kit, following the manufacturer’s
guidelines. Ion PI Sequencing 200 kit (Ion Torrent, Life Technolo-
gies). The Ion PI Chip (Ion Torrent) was prepared and calibrated for
loading. The Ion PI Chip was loaded with a template-positive ISPs
and run on the Ion Proton Sequencer.
Bioinformatic analysis
Bioinformatics analysis was carried out using several command
line software included in Bio-Linux (http://nebc.nerc.ac.uk/tools/
bio-linux/bio-linux-7-info). Using Star aligner, the reads, previously
filtered for quality and length, were processed and aligned to
mouse genome (mm10 version). The unmapped reads, generated
from the first step, were re-aligned by using Bowtie2. The reads
mapped with Star and Bowtie2 were merged and processed with
Cufflinks. Cufflinks uses the alignment file to assemble and recon-
struct the transcriptome. Cuffdiff (included in Cufflinks) was used
to calculate the differential gene expression between different
groups (0, 4, 24, and 96 h). Cuffdiff calculates expression in two
or more samples and tests the statistical significance of each
observed change in expression between them. The statistical
model used to evaluate changes assumes that the number of reads
produced by each transcript is proportional to its abundance but
fluctuates because of technical variability during library prepara-
tion and sequencing and because of biological variability between
replicates of the same experiment (Trapnell et al, 2012). RNA-seq
data have been deposited in the ArrayExpress database at
EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession number
E-MTAB-5730.
Droplet digital PCR
Droplet digital PCR (ddPCR) was carried out using the ddPCRTM
Supermix for Probes (No dUTP), the QX200TM Droplet Generator,
the QX200 Droplet Reader, the C1000 TouchTM Thermal Cycler, and
the PX1TM PCR Plate Sealer (Bio-Rad, Hercules, CA, USA) following
manufacturer’s instructions. Reactions were performed in triplicate
in a 96-well plate using 10 ll/reaction of 2× ddPCR Supermix for
Probes (No dUTP), 1 ll/reaction of 20× target primers/probe (FAM
or HEX, Bio-Rad), 1 ll/reaction of 20× reference primers/probe
(FAM or HEX, Bio-Rad), 3 ll cDNA and 5 ll H2O. Detection of
CXCL12 and GAPDH by ddPCR was performed using the following
PrimePCRTM ddPCRTM Expression Probe Assay designed by Bio-Rad:
CXCL12-FAM (ID: dMmuCPE511627, Bio-Rad) and GAPDH-HEX (ID:
dMmuCPE5195283, Bio-Rad). All steps used a ramp rate of 2°C/s.
Results were analyzed in the QX200 Droplet Reader, the RNA targets
were quantified using the QuantaSoftTM Software (Bio-Rad), and
results were expressed as fractional abundance.
NMJ immunohistochemistry
Anesthetized mice were locally injected close to LAL muscles with
a-LTx as described above. Muscles were dissected at different time
points and fixed in 4% PFA in PBS for 30 min at RT. Samples were
quenched, permeabilized, and saturated for 2 h in 15% goat serum,
2% BSA, 0.25% gelatine, 0.20% glycine, and 0.5% Triton X-100 in
PBS. Incubation with the primary antibodies was carried out for
72 h in blocking solution. Muscles were then washed and incubated
with secondary antibodies.
Images were collected with a Leica SP5 Confocal microscope
equipped with a 63× HCX PL APO NA 1.4. Laser excitation line,
power intensity, and emission range were chosen accordingly to
each fluorophore in different samples to minimize bleed-through.
RNA fluorescence in situ hybridization (FISH)
The Probe Designer tool was used to design a set of 48 oligonu-
cleotide probes (Quasar 570-conjugated) complementary to the
Mus musculus CXCL12a transcript (NM_021704.3). Stellaris RNA
FISH buffers and probes were purchased by LGC Biosearch Tech-
nologies. In situ hybridization was performed on 7 to 10-lm-thick
cryoslices according to the manufacturer’s guidelines for frozen
tissue. Images were collected as above.
Electrophysiological recordings
Electrophysiological recordings were performed in oxygenated
Krebs-Ringer solution on soleus muscles using intracellular glass
microelectrodes (WPI, Germany) filled with one part of 3 M KCl and
two parts of 3 M CH3COOK. To determine the time course of NMJ
degeneration and regeneration, anesthetized C57BL/6 female mice
(2 months of age) were locally injected with the toxin in the hind
limb (a-LTx 5 lg/kg), and soleus muscles were collected at 0, 4, 24,
and 96 h from treatment. In another set of experiments recordings
were performed on soleus muscles from mice i.p. injected with
100 lg of anti-CXCL12a antibody (diluted in 40 ll physiological
solution plus 0.2% gelatine) prior to the local injection of a-LTx.
For experiments with the CXCR4 antagonist, mice were i.p.
injected with 100 lg AMD3100 (in 40 ll physiological solution
containing 0.2% gelatine) prior to local injection of a-LTx.
AMD3100 administration was performed twice a day for 4 days.
To test the effect of chemokine administration on NMJ recovery,
rCXCL12a was locally injected in soleus muscle (100 ng, 15 ll injec-
tion volume) 8, 24, and 48 h post-a-LTx injection. Electrophysiologi-
cal recordings were performed after 72 h of intoxication.
Evoked neurotransmitter release was recorded in current-clamp
mode, and resting membrane potential was adjusted with current
injection to 70 mV. Evoked junction potentials (EJPs) were elicited
by supramaximal nerve stimulation at 0.5 Hz using a suction micro-
electrode connected to a S88 stimulator (Grass, USA). To prevent
muscle contraction after dissection, samples were incubated for
10 min with 1 lM l-Conotoxin GIIIB (Alomone, Israel). Signals
were amplified with intracellular bridge mode amplifier (BA-01X,
NPI, Germany), sampled using a digital interface (NI PCI-6221,
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National Instruments, USA) and recorded by means of electrophysi-
ological software (WinEDR, Strathclyde University). EJP measure-
ments were carried out with Clampfit software (Molecular Devices,
USA) and statistical analysis with Prism (GraphPad Software, USA).
Cell cultures and treatments
Primary cultures of SCMNs were prepared as described in Rigoni
et al (2004) and exposed for 24 h to rCXCL12a (500 ng/ml, R&D) in
culture medium. Low-density motor neuron cultures were used to
test the effect of rCXCL12a on axon growth. In some experiments,
AMD3100 (10 lM) was added to SCMNs together with rCXCL12a
that was kept throughout the experiment. After 24 h, neurons were
fixed and stained for b3-tubulin and axon growth quantified with
the ImageJ plugin NeuronJ.
Microfluidic chambers
Microfluidic chambers were produced using established methods
(Park et al, 2006). Polydimethylsiloxane (Dow Corning) inserts were
sterilized and fixed to 50-mm glass-bottomed WillCo dishes (IntraCel)
using plasma cleaning. The chambers were blocked with 0.8% BSA in
PBS overnight at 37°C and then coated with poly-L-ornithine and
laminin. SCMNs were plated in the somatic compartment. rCXCL12a
(500 ng/ml) was added to the distal compartment in the absence or
presence of AMD3100 (added to the somatic chamber, 10 lM).
Neurons were allowed to grow for 5 days, fixed, and stained for
b3-tubulin; axon growth was quantified with the ImageJ plugin NeuronJ.
Immunofluorescence
Cells were fixed for 15 min in 4% PFA in PBS, quenched (0.38%
glycine, 0.24% NH4Cl in PBS), and permeabilized with 0.3% Triton
X-100 in PBS for 5 min at room temperature. After saturation with
3% goat serum in PBS for 1 h, samples were incubated with
primary antibodies (anti-b3-tubulin, 1:200; anti-CXCR4, 1:500; anti-
GAP43, 1:200), diluted in 3% goat serum in PBS overnight at 4°C,
washed, and then incubated with the corresponding secondary anti-
bodies Alexa-conjugated for 1 h at room temperature. Coverslips
were mounted in Mowiol and examined by confocal (Leica SP5) or
epifluorescence (Leica CTR6000) microscopy.
Statistical analysis
Sample sizes were determined by analysis based on data collected
by our laboratory in published studies. In animal studies, we used
n = 6 mice/group for electrophysiological analysis. In cell culture
studies, we performed each study with at least five independent
replications. For all animal studies, we have ensured blinded
conduct of experiments. For imaging analysis, the quantitation was
conducted by an observer who was blind to the experimental
groups. No samples or animals were excluded from the analysis.
The sample size (N) of each experimental group is described in
the corresponding figure legend. Data displayed as histograms are
expressed as means  SEM or SD (represented as error bars).
GraphPad Prism software was used for all statistical analyses. Statis-
tical significance was evaluated using analysis of variance (ANOVA)
with Tukey post-test or two-tailed, unpaired Student’s t-test
depending on the number of groups to be analyzed. Data were
considered statistically different when *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001.
Expanded View for this article is available online.
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